Spondyloarthritis & psoriatic arthritis
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
Authors' conclusion
Treatment with guselkumab provided robust and sustained benefits across multiple PsA domains through 1 year, indicating that guselkumab is an effective therapy for the diverse manifestations of PsA.
Study context
- Population
- Patients with active PsADISCOVER-1 n = 381
- Comparison
- Guselkumab 100 mg Q4W or Q8W vs placebo
- Outcome
- Efficacy by composite indices:
- DAPSA
- Psoriatic Arthritis Disease Activity Score (PASDAS)
- Minimal disease activity (MDA)
- Very low disease activity (VLDA)
- Follow-up
- Through week 52
Methodological detailsplacebo-controlled, placebo crossover to guselkumab at week 24, non-responder imputation through week 52
- Placebo-controlled
- Placebo crossover to guselkumab at week 24
- Non-responder imputation through week 52
Pooled result
As reported in the abstract
DAPSA low disease activity (LDA) and remission, PASDAS LDA and VLDA, MDA, and VLDA · week 24
Greater proportions of guselkumab- than placebo-treated patients achieved each index
all unadjusted P < 0.05
Further pooled results
| Outcome | Guselkumab Q4W | Guselkumab Q8W |
|---|---|---|
| Composite index response rates · week 52Non-responder imputation for missing data | ||
| DAPSA LDA | 54.2% | 52.5% |
| DAPSA remission | 18.2% | 17.6% |
| PASDAS LDA | 45.3% | 41.9% |
| PASDAS VLDA | 16.9% | 19.5% |
| MDA | 35.9% | 30.7% |
| VLDA | 13.1% | 14.4% |
Composite index response rates after crossover to guselkumab · week 24 through week 52
- Placebo-crossover: response rates for all composite indices increased after switching to guselkumab
Original publication
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford). Published 29 June 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →